Further contract for Cleveland BioLabs

September 16, 2008 by · Comment
Filed under: Cleveland BioLabs, Contract Awards, Department of Defense, development program, medicine 

Cleveland BioLabs, who won a DoD contract earlier this year, was awarded a further contract from the US Department of Health and Human Services to work on their drug to counter the effects of radiation exposure. This contract is worth over $13 M and builds on the $9 M one from earlier this year.

For more see Buffalo Business First here.

Tags: , , , , , , , , ,

Perseverance Pays

April 4, 2008 by · 1 Comment
Filed under: Cleveland BioLabs, Contract Awards, Department of Defense, development program 

Cleveland Biolabs who at the beginning of the year failed to win a large contract from DoD for a drug to treat radiation poisoning was rewarded yesterday with another contract. See the article here. A previous post on the matter can be found here. This contract worth about $9 M pales compared to the one awarded previously at $225 M but will help the company move forward with its research. Read more

Tags: , , , , , ,

Osiris defense contract makes company take off

January 12, 2008 by · Comment
Filed under: Cleveland BioLabs, Contract Awards, development program, Osiris Therapuetics 

As previously discussed, the contract Osriris won from DoD for a drug to treat radiation damage to the gastrointestinal system has really caused the company and its stock to take off. See previous posts here and here for more detail. The contract could be worth $225 M initially, and if the US Government decides to use it for civilian use the value could be unlimited. See CNNMoney.com for more.

Tags:

Cleveland BioLabs Loses Out to Osiris For Radiation Treatment Contract

January 4, 2008 by · 2 Comments
Filed under: Cleveland BioLabs, Contract Awards, Department of Defense, medicine, Osiris Therapuetics 

As we reported earlier today, Osiris Therapeutics won a Department of Defense contract to develop a treatment for radiation sickness. Unfortunately, Osiris’s gain was Cleveland BioLabs’ loss. Cleveland’s “shares plummeted nearly 60% after the Buffalo, N.Y., company’s proposed treatment for the gastrointestinal effects of radiation sickness, Protectan CBLB502, wasn’t chosen.” More details at The Street.

Tags: , ,

>